Currently the SAM is an agency under the Ministry of Social Affairs. The SAM has 9 departments and over 130 employees. Our main office is in Tartu, but there is an office in Tallinn as well. The Director General of the SAM is Katrin Kiisk.
The State Agency of Medicines (SAM) is a governmental body with the aim to
-
Help people understand issues related to medicines and medical devices.
-
Monitor the efficacy, quality, and safety of medicines and grants marketing authorisations.
-
Ensure that medical devices used by people are effective and safe.
-
Assess the eligibility of clinical trials for medicines and investigations involving medical devices.
-
Issue licences for the handling of medicines and ensures compliance with relevant requirements.
-
Evaluate the efficacy, quality, and safety of medicines both at the time of marketing authorisation and during their presence on the market.
-
Collect and analyses data on incidents involving medical devices.
- Collect and analyse data on the use of medicines and adverse drug reactions, and assesses the relationship between vaccines and side effects in the context of vaccine injury compensation.
-
Monitor the movement of medicines, narcotic and psychotropic substances, and their precursors across the Estonian border.
-
Oversee the procurement and handling of blood, cells, tissues, and organs.
-
Ensure compliance with advertising regulations for medicines and medical devices and supervises the functioning of pharmacovigilance systems maintained by marketing authorisation holders.
-
Represent Estonia in the committees of the European Medicines Agency, the European Pharmacopoeia, and other bodies, as well as in the working groups of the European regulatory network for medicines and medical devices.
Mission of the State Agency of Medicines
The mission of the State Agency of Medicines is to protect human and animal health by promoting the proper use of medicines and medical devices and supporting the development of the sector.
Vision of the State Agency of Medicines
The Medicines Agency brings together leading, internationally recognised experts whose expertise, competence, and values ensure the continued development of the medicines and medical devices sector and foster responsible and informed use of medicines.
Values of the State Agency of Medicines
Competence
- We base our work on relevant scientific data and legislation and use the best expertise available in Estonia.
- We constantly update our knowledge and operating methods.
- We are aware that our every action reflects on the State Agency of Medicines and remember that our decisions have a significant impact.
Reliability
- We consider all known aspects when making decisions and we are impartial towards our partners and colleagues.
- We look for substantive solutions and keep our promises.
- We analyze our decisions, admit our mistakes and learn from them.
Efficiency
- We actively identify the areas in which we can be of assistance.
- We have a say in important discussions and initiate necessary changes.
- We value our own, our colleagues’ and our partners’ time.
- We complete what we start.
Cooperation
- We guide ourselves by the main purpose of the State Agency of Medicines to protect public health while contributing to the development of research and entrepreneurship in Estonia with our knowledge.
- We recognise opportunities for cooperation and are open to relevant suggestions.
- We value the expectations of our cooperation partners and adhere to agreements.
Overview of Departments
Development and Administration Department
The Development and Administration Department manages the planning, implementation, and deployment of the agency’s IT development projects, including information systems; data management; development and testing of new IT solutions; human resources and document management. The department maintains the agency’s archive, manages state property under the agency's control and organizes its maintenance; coordinates public procurement procedures; ensures secretarial services for the agency, and carries out other support functions necessary for fulfilling the agency’s duties.
Supervision Department
The Supervision Department oversees the activities of medicine handlers and handlers of narcotic drug precursors, including the issuance of operating licenses. It is also responsible for the supervision of cross-border movement of medicines. The department handles product classification and the issuance of permits related to personal use (e.g., traveling with medicines and postal shipments). In addition, it deals with notifications regarding medicine supply disruptions and oversees the conduct of clinical trials.
Medical Devices Department
The Medical Devices Department maintains the national registry of medical devices, collects and analyzes data on adverse incidents related to medical devices, resolves classification issues, and evaluates technical documentation of devices. The department also assesses applications for clinical investigations and derogations related to medical devices and supervises businesses operating in the medical devices sector.
Legal Department
The Legal Department ensures the legality of the agency’s services in the interpretation and application of legislation and in supervisory activities. It represents the agency in legal proceedings and other legal matters or discussions. The department participates in the legislative process concerning pharmaceutical law and represents the agency in international cooperation according to its area of competence.
Marketing Authorisations Department
The Marketing Authorisations Department conducts scientific assessments of marketing authorisation and clinical trial applications. Following a positive assessment, a marketing authorisation or a clinical trial authorisation is granted in Estonia. The department also supervises the conduct of clinical trials.
Biological Preparations Department
The Biological Preparations Department oversees the production of blood components and the procurement and handling of human-derived cells, tissues, and organs, including safety monitoring. The department is also responsible for matters related to advanced therapy medicinal products.
Laboratory
The agency’s laboratory controls the quality of medicines and substances used in the manufacture of medicines and participates in the work of the European Pharmacopoeia and the official medicines control laboratories network of the Council of Europe.
Pharmacovigilance Department
The Pharmacovigilance Department monitors the safety of medicines and investigates their use.
Quality Management System
Our quality management system is committed to the implementation and maintenance of a documented quality management system which is continually improved. The system is based on the requirements of the legislation, the regulatory system and ISO 9001; it also takes into account guidelines, standards and best practices from Estonian and international organizations.
The quality system is implemented and operated by all agency`s staff. Internal audits help to provide quality assurance to management that the system is operating effectively, and contributes to the improvement of systems and processes.
Benchmarking
The Heads of the European Medicines Agencies have established a benchmarking exercise, the aim of which is to contribute to the development of a world-class pharmaceutical regulatory system, based on a network of agencies, operating to the best practice standards.
The benchmarking of European Medicines Agencies (BEMA) is based on a self-assessment in four areas: organization and management; assessment of marketing authorization applications; pharmacovigilance and inspections. The internal self-assessments are then followed up by external peer-reviews. Reports from all the visited agencies are entered into a database which forms a valuable resource for best practice across the entire EU/EEA network of medicines agencies.
OMCL
Our laboratory is accredited according to the EVS-EN ISO/IEC 17025:2017 by the Estonian Accreditation Centre (accreditation certificate no L217.) The Scope of the accreditation is given in the annex to the accreditation certificate.
The main vision for 2026 The Agency employs the best internationally recognised experts whose expertise, skills and values contribute to the development of the pharmaceutical sector as well as pharmaceutical awareness.
Priority development areas and goals of the Agency in 2023–2026:
-
Drug information providing added value
- We improve public awareness of the Agency as a source of reliable drug information, and know what information various stakeholders need
- We improve patients’ drug-awareness, and thereby their engagement in the treatment process
- nformation on clinical trials and trial sites is available to potential subjects as well as doctors
-
Being an innovative and valued partner
- Strengthening the advisory aspect of supervision
- Improving scientific advisory capability
- Proposals to update regulations and provide room for discretion on the European Union level as well as in Estonia.
-
Long-term state capability for directing and developing the pharmaceutical field
- Attractiveness as an employer
- Efficient organisation of work, potential replacements for all roles
- Developing environmental awareness in the Agency
-
European Medicines Agency (EMA)
The European Medicines Agency (EMA) coordinates the scientific evaluation, supervision and safety monitoring of medicines in the European Union. The State Agency of Medicines contributes to the work of EMA through its participation in scientific committees and working groups together with other national competent authorities. EMA’s recommendations form the basis for European Commission decisions on the authorisation and safety of medicines across the EU.
Further information is available on the EMA website.
-
Heads of Medicines Agencies (HMA)
The focus of the HMA, in which all heads of the medicines agencies of the European Economic Area (EEA) are represented, is on the continuous professional exchange among the agencies. Several working groups (HMA Working Groups) have been established for this purpose.
Further information can be found on the HMA website
-
EMRN and Global Regulatory Cooperation
The European Medicines Regulatory Network (EMRN) embraces and actively supports cooperation with regulatory authorities in third countries. This collaboration aims to strengthen global regulatory systems, promote mutual reliance, and enhance public health worldwide.
For direct contact with other National Competent Authorities (NCAs) within the EMRN, please refer to the NCA Contact List on the HMA website, available here.
-
Pharmacovigilance Risk Assessment Committee (PRAC)
The Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for evaluating all safety aspects related to human medicinal products. This includes the recognition and evaluation of safety signals and their assessment with regard to the benefit-risk ratio of medicinal specialities as well as the selection, introduction and communication of risk-minimising measures and the planning and evaluation of safety studies and pharmacovigilance inspections.
The recommendations of this committee form the basis for the decisions of the CHMP and the CMD(h) in all safety-relevant matters. Decisions are taken either by consensus or by majority decision.
Further information can be found on the PRAC page.
Yearbooks
The yearbooks of the State Agency of Medicines highlights the major accomplishments of the past year and offers a comprehensive overview of each department's activities.
Last updated: 05.05.2026